Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

[1]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[2]  G. Keating,et al.  Prolonged-Release Nicotinic Acid , 2012, Drugs.

[3]  Michael Müller,et al.  Peroxisome Proliferator-Activated Receptor Alpha Target Genes , 2010, PPAR research.

[4]  P. Barter,et al.  Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database , 2010, Journal of Lipid Research.

[5]  A. Kontush,et al.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors , 2009, European heart journal.

[6]  M. Laakso,et al.  Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. , 2010, European heart journal.

[7]  R. Blumenthal,et al.  The HALTS trial--halting atherosclerosis or halted too early? , 2009, The New England journal of medicine.

[8]  J. Kastelein,et al.  Statin therapy with ezetimibe or niacin in high-risk patients. , 2009, The New England journal of medicine.

[9]  Michael Miller,et al.  Extended-release niacin or ezetimibe and carotid intima-media thickness. , 2009, The New England journal of medicine.

[10]  B. G. Brown,et al.  Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed For , 2009, The American journal of cardiology.

[11]  M. Robson,et al.  Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. , 2009, Journal of the American College of Cardiology.

[12]  F. Jaffer.  Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging. , 2009, Journal of the American College of Cardiology.

[13]  P. Barter,et al.  Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. , 2009, Archives of internal medicine.

[14]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[15]  Børge G Nordestgaard,et al.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[16]  O. Raitakari,et al.  HDL-Cholesterol, Blood Pressure, and Asymmetric Dimethylarginine Are Significantly Associated With Arterial Wall Thickness in Children , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[17]  A. Kontush,et al.  Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[18]  J. Violin,et al.  beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. , 2009, The Journal of clinical investigation.

[19]  J. Goldstein,et al.  The LDL receptor. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[20]  Benjamin J. Wright,et al.  Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease , 2009, Nature Genetics.

[21]  V. Feigin,et al.  Does cigarette smoking exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the risk of cardiovascular diseases? , 2009, Heart.

[22]  N. Fournier,et al.  Torcetrapib Differentially Modulates the Biological Activities of HDL2 and HDL3 Particles in the Reverse Cholesterol Transport Pathway , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[23]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[24]  Lin-hua Zhang,et al.  Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. , 2009, Atherosclerosis.

[25]  R. Pasternak,et al.  Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia , 2008, International journal of clinical practice.

[26]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[27]  J. Jukema,et al.  Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[28]  G. Watts,et al.  Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[29]  K. Williams.  Molecular processes that handle -- and mishandle -- dietary lipids. , 2008, The Journal of clinical investigation.

[30]  Subramaniam Pennathur,et al.  Combined Statin and Niacin Therapy Remodels the High-Density Lipoprotein Proteome , 2008, Circulation.

[31]  P. Giral,et al.  Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. , 2008, Pharmacogenomics.

[32]  A. Lichtenstein,et al.  Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[33]  Alberto Zambon,et al.  Fibrates and future PPARα agonists in the treatment of cardiovascular disease , 2008, Nature Clinical Practice Cardiovascular Medicine.

[34]  V. Kamanna,et al.  Nicotinic acid: recent developments , 2008, Current opinion in cardiology.

[35]  P. Jones,et al.  Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit , 2008, Cardiovascular Drugs and Therapy.

[36]  A. Kontush,et al.  Spotlight on HDL-raising therapies: insights from the torcetrapib trials , 2008, Nature Clinical Practice Cardiovascular Medicine.

[37]  Lin-hua Zhang,et al.  Niacin inhibits surface expression of ATP synthase β chain in HepG2 cells: implications for raising HDL This study was supported by grants from the Southern California Institute for Research and Education. Published, JLR Papers in Press, March 3, 2008. , 2008, Journal of Lipid Research.

[38]  J. Mckenney,et al.  Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). , 2008, The American journal of cardiology.

[39]  C. Wentworth,et al.  Dosage, titration, and gaps in treatment with extended release niacin in clinical practice* , 2008, Current medical research and opinion.

[40]  P. Libby.  The molecular mechanisms of the thrombotic complications of atherosclerosis , 2008, Journal of internal medicine.

[41]  B. G. Brown,et al.  Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. , 2008, The American journal of cardiology.

[42]  V. Kamanna,et al.  Mechanism of action of niacin. , 2008, The American journal of cardiology.

[43]  C. Ballantyne,et al.  Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. , 2008, The American journal of cardiology.

[44]  A. Sposito,et al.  Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. , 2008, Pharmacology & therapeutics.

[45]  Christopher P Cannon,et al.  Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. , 2008, Journal of the American College of Cardiology.

[46]  Pierre Amarenco,et al.  High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. , 2008, Atherosclerosis.

[47]  S. Offermanns,et al.  Nicotinic acid: pharmacological effects and mechanisms of action. , 2008, Annual review of pharmacology and toxicology.

[48]  P. Barter,et al.  Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[49]  S. Ferranti.  Drug Therapy for Hypercholesterolemia and Dyslipidemia , 2008 .

[50]  S. Allender,et al.  European cardiovascular disease statistics , 2008 .

[51]  K. Furie,et al.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.

[52]  John A Wagner,et al.  Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies , 2007, The Lancet.

[53]  D. Hommes,et al.  Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease Published, JLR Papers in Press, September 22, 2007. , 2007, Journal of Lipid Research.

[54]  Peter Libby,et al.  Inflammatory mechanisms: the molecular basis of inflammation and disease. , 2007, Nutrition reviews.

[55]  P. Mitchell,et al.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.

[56]  H. Brewer,et al.  HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease , 2007, Current cardiology reports.

[57]  R. Arora,et al.  The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. , 2007, American heart journal.

[58]  J. Ferrières,et al.  Cost‐effectiveness of raising HDL cholesterol by adding prolonged‐release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective , 2007, International journal of clinical practice.

[59]  G. Umpierrez,et al.  The effects of extended‐release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome , 2007, International journal of clinical practice.

[60]  R. Luben,et al.  Apolipoprotein A-II Is Inversely Associated With Risk of Future Coronary Artery Disease , 2007, Circulation.

[61]  J. Borén,et al.  Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update , 2007 .

[62]  Mitsuko Masutani,et al.  PolyADP‐ribosylation and cancer , 2007, Cancer science.

[63]  R. Wolfert,et al.  Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2 , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[64]  A. Gotto,et al.  HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2007, The New England journal of medicine.

[65]  J. Brunzell,et al.  Clinical practice. Hypertriglyceridemia. , 2007, The New England journal of medicine.

[66]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) , 2007 .

[67]  E. Topol,et al.  A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[68]  Inder Singh,et al.  High-density lipoprotein as a therapeutic target: a systematic review. , 2007, JAMA.

[69]  Ling Liu,et al.  Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase Published, JLR Papers in Press, May 13, 2007. , 2007, Journal of Lipid Research.

[70]  K. Borucki,et al.  Extended-release niacin raises adiponectin and leptin. , 2007, Atherosclerosis.

[71]  F. Kronenberg,et al.  Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[72]  P. Ridker,et al.  Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.

[73]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[74]  W. Koenig.  Cardiovascular Biomarkers: Added Value With an Integrated Approach? , 2007, Circulation.

[75]  D. Connolly,et al.  Nicotinic Acid Receptor Agonists Differentially Activate Downstream Effectors* , 2007, Journal of Biological Chemistry.

[76]  D. Bruemmer,et al.  PPARα Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes , 2007, Diabetes.

[77]  Mario A. González,et al.  Effect of the Rate of Niacin Administration on the Plasma and Urine Pharmacokinetics of Niacin and Its Metabolites , 2007, Journal of clinical pharmacology.

[78]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[79]  G. O'neill,et al.  Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1 , 2007, Clinical pharmacology and therapeutics.

[80]  X. Adiconis,et al.  Fenofibrate Effect on Triglyceride and Postprandial Response of Apolipoprotein A5 Variants: The GOLDN Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[81]  R. Hegele,et al.  Apolipoprotein A-V genetic variation and plasma lipoprotein response to fibrates. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[82]  S. Wright,et al.  Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. , 2007, Biochemical and biophysical research communications.

[83]  Allen J. Taylor,et al.  Design and Rationale of the ARBITER 6 Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS) , 2007, Cardiovascular Drugs and Therapy.

[84]  H. Bays,et al.  Safety considerations with niacin therapy. , 2007, The American journal of cardiology.

[85]  J. Mckenney,et al.  Safety considerations with fibrate therapy. , 2007, The American journal of cardiology.

[86]  B. G. Brown,et al.  Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence. , 2007, Journal of clinical lipidology.

[87]  C. Gibson,et al.  Fibrates: What Have We Learned in the Past 40 Years? , 2007, Pharmacotherapy.

[88]  Subramaniam Pennathur,et al.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.

[89]  Paul Schoenhagen,et al.  Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. , 2007, JAMA.

[90]  Vincent J. Willey,et al.  Risk of cardiovascular events in patients at optimal values for combined lipid parameters , 2007, Current medical research and opinion.

[91]  M. Farnier,et al.  Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. , 2007, American heart journal.

[92]  C. Luley,et al.  Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels , 2007, Vascular health and risk management.

[93]  J. Danesh,et al.  Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.

[94]  R. Young,et al.  Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). , 2007, Journal of medicinal chemistry.

[95]  Fernando Costa,et al.  Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus , 2007, Diabetes Care.

[96]  James E. Muller,et al.  Detection and Treatment of Vulnerable Plaques and Vulnerable Patients: Novel Approaches to Prevention of Coronary Events , 2006, Circulation.

[97]  Allen J. Taylor,et al.  The effect of 24 months of combination statin and extended-release niacin on carotid intima‐media thickness: ARBITER 3* , 2006, Current medical research and opinion.

[98]  H. Brewer,et al.  Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. , 2006, The American journal of cardiology.

[99]  M. Chapman.  Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. , 2006, Pharmacology & therapeutics.

[100]  Y. Deshaies,et al.  Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia. , 2006, Atherosclerosis.

[101]  R. McPherson,et al.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. , 2006, The Canadian journal of cardiology.

[102]  A. Kontush,et al.  Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.

[103]  G. Watts,et al.  Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. , 2006, Clinical science.

[104]  H. Bloomfield,et al.  Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials , 2006, Current opinion in lipidology.

[105]  R. Maranhão,et al.  Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment. , 2006, Atherosclerosis.

[106]  Ira Tabas,et al.  Letter by Williams and Tabas regarding article "atherosclerosis 2005: recent discoveries and novel hypotheses". , 2006, Circulation.

[107]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[108]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. , 2006, Circulation.

[109]  R. D'Agostino,et al.  Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Studys⃞ , 2006, Journal of Lipid Research.

[110]  B. Lamarche,et al.  Effect of Ezetimibe on the In Vivo Kinetics of ApoB-48 and ApoB-100 in Men With Primary Hypercholesterolemia , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[111]  Alberto Zambon,et al.  Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–&agr; Activators: Clinical and Experimental Evidence , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[112]  G. O'neill,et al.  Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[113]  R. Virmani,et al.  Pathology of the Vulnerable Plaque , 2006 .

[114]  M. Bottorff,et al.  Statin safety and drug interactions: clinical implications. , 2006, The American journal of cardiology.

[115]  M. Bamberger,et al.  Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of actions⃞ , 2006, Journal of Lipid Research.

[116]  C. Furberg,et al.  Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). , 2006, The American journal of cardiology.

[117]  G. Nichols,et al.  The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up. , 2006, Clinical therapeutics.

[118]  M. Davidson.  Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions , 2006, Expert opinion on drug safety.

[119]  M. Chapman.  Fibrates: therapeutic review , 2006 .

[120]  M. Chapman,et al.  Review: Fibrates: therapeutic review , 2006 .

[121]  Diabetes Uk,et al.  JBS 2: Joint British Societies9 guidelines on prevention of cardiovascular disease in clinical practice , 2005 .

[122]  Z. Benyó,et al.  GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. , 2005, The Journal of clinical investigation.

[123]  Paul Zimmet,et al.  [A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results]. , 2005, Revista espanola de cardiologia.

[124]  N. Pike.  Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. , 2005, The Journal of clinical investigation.

[125]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[126]  M. Creager,et al.  Atherosclerosis 2005: recent discoveries and novel hypotheses. , 2005, Circulation.

[127]  E. Bruckert,et al.  High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients , 2005, Current medical research and opinion.

[128]  Peter Libby,et al.  The forgotten majority: unfinished business in cardiovascular risk reduction. , 2005, Journal of the American College of Cardiology.

[129]  Serkalem Demissie,et al.  Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[130]  Zahi A Fayad,et al.  Atherothrombosis and high-risk plaque: part I: evolving concepts. , 2005, Journal of the American College of Cardiology.

[131]  B. Staels,et al.  Pleiotropic effects of fibrates , 2005, Current atherosclerosis reports.

[132]  J. Frostegård.  Atherosclerosis in Patients With Autoimmune Disorders , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[133]  L. Carlson,et al.  Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review , 2005, Journal of internal medicine.

[134]  E. Brilakis,et al.  Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. , 2005, The New England journal of medicine.

[135]  M. McGovern.  Niaspan®: creating a new concept for raising HDL-cholesterol , 2005 .

[136]  J. Chapman.  Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia , 2005 .

[137]  B. G. Brown,et al.  Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy , 2005 .

[138]  D. Rader,et al.  New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport , 2005, Circulation research.

[139]  M. Hussain,et al.  Intestinal lipoprotein assembly , 2005, Current opinion in lipidology.

[140]  H. Rotmensch,et al.  Bezafibrates Cause Moderate, Reversible Impairment in Renal Function in Patients without Prior Renal Disease , 2005, Nephron Clinical Practice.

[141]  L. V. Van Gaal,et al.  Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel , 2005, Current medical research and opinion.

[142]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[143]  T. Twickler,et al.  Remnant lipoproteins and atherosclerosis , 2005, Current atherosclerosis reports.

[144]  S. Grundy,et al.  Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). , 2005, The American journal of cardiology.

[145]  C. Gibson,et al.  Optimal Lipid Modification: The Rationale for Combination Therapy , 2005, Vascular health and risk management.

[146]  J. Kastelein,et al.  Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. , 2005, Journal of the American College of Cardiology.

[147]  A. Gotto,et al.  A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events , 2005, Annals of Internal Medicine.

[148]  C. Furberg,et al.  Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). , 2005, The American journal of cardiology.

[149]  G. Assmann.  Beyond statin therapy: why we need new thinking , 2005, Current medical research and opinion.

[150]  Jeannie K. Lee,et al.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.

[151]  M. Woodward,et al.  Serum Triglycerides as a Risk Factor for Cardiovascular Diseases in the Asia-Pacific Region , 2004, Circulation.

[152]  D. Capuzzi,et al.  The effects of niacin on lipoprotein subclass distribution. , 2004, Preventive cardiology.

[153]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[154]  D. Fordyce,et al.  A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions. , 2004, Clinical therapeutics.

[155]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[156]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[157]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[158]  G. Assmann,et al.  Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C* , 2004, Current medical research and opinion.

[159]  P. Thompson,et al.  Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. , 2004, Archives of internal medicine.

[160]  P. Touboul,et al.  Stroke prevention, blood cholesterol, and statins , 2004, The Lancet Neurology.

[161]  G. Dallinga-Thie,et al.  Elevated Remnant-Like Particle Cholesterol Concentration: A Characteristic Feature of the Atherogenic Lipoprotein Phenotype , 2004, Circulation.

[162]  Robert Kleemann,et al.  Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-α Activator Fenofibrate* , 2004, Journal of Biological Chemistry.

[163]  J. Mckenney.  New perspectives on the use of niacin in the treatment of lipid disorders. , 2004, Archives of internal medicine.

[164]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[165]  N. Pike,et al.  Identification of a nicotinic acid receptor: is this the molecular target for the oldest lipid-lowering drug? , 2004, Current opinion in investigational drugs.

[166]  M. Linton,et al.  The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy , 2004, Current atherosclerosis reports.

[167]  C. Luley,et al.  The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. , 2004, Expert opinion on drug safety.

[168]  T. Sand,et al.  Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[169]  Luquan Wang,et al.  Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption , 2022 .

[170]  M. Trottmann,et al.  Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. , 2004, Biochemical pharmacology.

[171]  U. Keller,et al.  Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia Published, JLR Papers in Press, October 1, 2003. DOI 10.1194/jlr.M300309-JLR200 , 2004, Journal of Lipid Research.

[172]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[173]  M. Guerin,et al.  Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. , 2004, Pharmacology & therapeutics.

[174]  S. Mochizuki,et al.  Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study. , 2004, Journal of atherosclerosis and thrombosis.

[175]  S. Haffner.  Dyslipidemia management in adults with diabetes. , 2004, Diabetes care.

[176]  C. Packard,et al.  Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. , 2003, Atherosclerosis.

[177]  G. Assmann,et al.  Atheroprotective effects of high-density lipoproteins. , 2003, Annual review of medicine.

[178]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[179]  R. Rosenson.  Antiatherothrombotic effects of nicotinic acid. , 2003, Atherosclerosis.

[180]  M. Chapman.  Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. , 2003, Atherosclerosis.

[181]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[182]  Antonio Colombo,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. , 2003, Circulation.

[183]  D. Hadizadeh,et al.  Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome , 2003, Clinical pharmacology and therapeutics.

[184]  J. Kirkland.  Niacin and Carcinogenesis , 2003, Nutrition and cancer.

[185]  D. Capuzzi,et al.  Effects of extended-release niacin on lipoprotein subclass distribution. , 2003, The American journal of cardiology.

[186]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[187]  D. Hunninghake,et al.  A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin , 2003, Clinical cardiology.

[188]  G. Watts,et al.  Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. , 2003, Diabetes.

[189]  W. Simpson,et al.  Statin-fibrate combination therapy for hyperlipidaemia: a review , 2003, Current medical research and opinion.

[190]  James W. Anderson,et al.  Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). , 2002, Archives of internal medicine.

[191]  M. Beylot,et al.  Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. , 2002, Diabetes.

[192]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[193]  T. Meade,et al.  Bezafibrate in men with lower extremity arterial disease: randomised controlled trial , 2002, BMJ : British Medical Journal.

[194]  A. van Tol,et al.  Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state DOI 10.1194/jlr.M200135-JLR200 , 2002, Journal of Lipid Research.

[195]  A. Sposito,et al.  Statin Therapy in Acute Coronary Syndromes: Mechanistic Insight Into Clinical Benefit , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[196]  M. Charles,et al.  Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. , 2002, Metabolism: clinical and experimental.

[197]  S. Grundy,et al.  Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. , 2002, Archives of internal medicine.

[198]  F. Sacks,et al.  The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. , 2002, The American journal of cardiology.

[199]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[200]  R. Karas,et al.  A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. , 2002, American heart journal.

[201]  V. Athyros,et al.  Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. , 2002, Diabetes care.

[202]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[203]  G. Lewis,et al.  Lipolytically Modified Triglyceride-Enriched HDLs Are Rapidly Cleared From the Circulation , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[204]  V. Athyros,et al.  Atorvastatin versus Four Statin–Fibrate Combinations in Patients with Familial Combined Hyperlipidaemia , 2002, Journal of cardiovascular risk.

[205]  M. Elisaf,et al.  Effects of Fibrates on Serum Metabolic Parameters , 2002, Current medical research and opinion.

[206]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[207]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[208]  A. Sharrett,et al.  Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Circulation.

[209]  D. Corella,et al.  Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. , 2001, Atherosclerosis.

[210]  Allen Shek,et al.  Statin—Fibrate Combination Therapy , 2001, The Annals of pharmacotherapy.

[211]  E. Angles-cano,et al.  Inhibition of Fibrinolysis by Lipoprotein(a) , 2001, Annals of the New York Academy of Sciences.

[212]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[213]  Diabetes Atherosclerosis Intervention Study Investigators.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.

[214]  H. Davis,et al.  The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. , 2001, European journal of pharmacology.

[215]  S. Myong,et al.  Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. , 2001, American journal of physiology. Endocrinology and metabolism.

[216]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[217]  P. Shah,et al.  Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization , 2001, Circulation.

[218]  D. Rader,et al.  Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. , 2001, The American journal of cardiology.

[219]  P. Giral,et al.  Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. , 2001, Atherosclerosis.

[220]  M. Jaye,et al.  PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.

[221]  D. Sprecher.  Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. , 2000, The American journal of cardiology.

[222]  D. Abramowicz,et al.  Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[223]  D. Hunninghake,et al.  Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. , 2000, JAMA.

[224]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[225]  Bezafibrate Infarction Prevention study.  Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[226]  Wei Wang,et al.  Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women. , 2000, American journal of physiology. Endocrinology and metabolism.

[227]  A. Tedgui,et al.  CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. , 2000, Circulation.

[228]  M. Krempf,et al.  Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia. , 2000, Diabetes & metabolism.

[229]  A. Goldberg,et al.  Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. , 2000, The American journal of cardiology.

[230]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[231]  M. Hellerstein,et al.  Erratum: Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women (American Journal of Physiology-Endocrinology and Metabolism (July 2000) 42 (E50-E59)) , 2000 .

[232]  Aldons J. Lusis,et al.  Atherosclerosis : Vascular biology , 2000 .

[233]  C. Packard,et al.  Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrate , 1999, Diabetes/metabolism research and reviews.

[234]  R. Knopp.  Drug treatment of lipid disorders. , 1999, The New England journal of medicine.

[235]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[236]  G. Lewis,et al.  HDL metabolism in hypertriglyceridemic states: an overview. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[237]  A. Hamsten,et al.  Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[238]  G. Lewis,et al.  Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. , 1999, The Journal of clinical investigation.

[239]  B. G. Brown,et al.  Relationship between plasma phospholipid transfer protein activity and HDL subclasses among patients with low HDL and cardiovascular disease. , 1999, Atherosclerosis.

[240]  R. Mahley,et al.  Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. , 1999, Journal of lipid research.

[241]  J Auwerx,et al.  Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.

[242]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[243]  C. O'connor,et al.  Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. , 1998, The American journal of cardiology.

[244]  A. Goldberg,et al.  Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. , 1998, Metabolism: clinical and experimental.

[245]  E. Schaefer,et al.  Diet, lipoproteins, and coronary heart disease. , 1998, Endocrinology and metabolism clinics of North America.

[246]  M. Phillips,et al.  Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. , 1998, Biochemistry.

[247]  B. G. Brown,et al.  Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction A 10-year Familial Atherosclerosis Treatment Study follow-up , 1998 .

[248]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[249]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[250]  P. Durrington,et al.  Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. , 1998, Atherosclerosis.

[251]  A. Gotto,et al.  Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. , 1998, The American journal of cardiology.

[252]  A. Nicolaides,et al.  Cardiovascular Outcomes in Type 2 Diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study , 1998, Diabetes Care.

[253]  J. Mckenney,et al.  A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. , 1998, The American journal of medicine.

[254]  J. Spence,et al.  Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates) , 1998, Clinical pharmacokinetics.

[255]  C. Packard,et al.  Lipoprotein heterogeneity and apolipoprotein B metabolism. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[256]  C. Packard,et al.  Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[257]  M. Nieminen,et al.  Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.

[258]  T. Simmet,et al.  Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes. , 1997, Blood.

[259]  R. Rosenson,et al.  Lipoprotein Lp(a) excess and coronary heart disease. , 1997, Archives of internal medicine.

[260]  W. Mack,et al.  The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[261]  J. Boer,et al.  Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[262]  B. Nordestgaard,et al.  Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. , 1996, Stroke.

[263]  H. Boudoulas,et al.  Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease , 1996, Coronary artery disease.

[264]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[265]  J Auwerx,et al.  The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. , 1996, Biochimica et biophysica acta.

[266]  A. von Eckardstein,et al.  High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. , 1996, Atherosclerosis.

[267]  D. Capuzzi,et al.  Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients With Hypercholesterolemia: A Placebo-controlled Trial. , 1996, Journal of cardiovascular pharmacology and therapeutics.

[268]  E. Bruckert,et al.  Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[269]  J Auwerx,et al.  Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. , 1996, Journal of lipid research.

[270]  A. Hamsten,et al.  Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients , 1996, The Lancet.

[271]  G. Dagenais,et al.  Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study. , 1996, Atherosclerosis.

[272]  M. Alegret,et al.  Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guinea‐pigs , 1995, British journal of pharmacology.

[273]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[274]  K. Williams,et al.  The response-to-retention hypothesis of early atherogenesis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[275]  D. Rader,et al.  Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[276]  E. Jacobson,et al.  Evaluating the role of niacin in human carcinogenesis. , 1995, Biochimie.

[277]  G. Schonfeld,et al.  The effects of fibrates on lipoprotein and hemostatic coronary risk factors. , 1994, Atherosclerosis.

[278]  R. Havel,et al.  Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[279]  C. Packard,et al.  Effects of ciprofibrate on LDL metabolism in man. , 1994, Atherosclerosis.

[280]  C. Packard,et al.  Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. , 1994, Atherosclerosis.

[281]  B. Ames,et al.  Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[282]  C. Packard,et al.  Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[283]  J. Hendriks,et al.  Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[284]  E. Bruckert,et al.  Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. , 1993, Atherosclerosis.

[285]  E. Bruckert,et al.  Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. , 1993, Journal of lipid research.

[286]  K. Steyn,et al.  Musculoskeletal manifestations in hyperlipidaemia: a controlled study. , 1993, Annals of the rheumatic diseases.

[287]  Betteridge Dj.  Ciprofibrate--a profile. , 1993 .

[288]  W. Castelli.  Epidemiology of triglycerides: a view from Framingham. , 1992, The American journal of cardiology.

[289]  J. K. Dunn,et al.  Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[290]  J. Huttunen,et al.  Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study , 1992, Diabetes Care.

[291]  D. Matthews,et al.  Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. , 1992, BMJ.

[292]  G. Luc,et al.  A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. , 1992, Metabolism: clinical and experimental.

[293]  P. Lesnik,et al.  Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. , 1991, Journal of lipid research.

[294]  M J Malloy,et al.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.

[295]  C. Packard,et al.  Postprandial lipemia, fenofibrate and coronary artery disease. , 1990, Atherosclerosis.

[296]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[297]  S. Grundy,et al.  Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. , 1990, JAMA.

[298]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.

[299]  G. Rosenhamer,et al.  Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. , 2009, Acta medica Scandinavica.

[300]  J. Huttunen,et al.  Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. , 1988, JAMA.

[301]  S. Grundy,et al.  Fibric acids: effects on lipids and lipoprotein metabolism. , 1987, The American journal of medicine.

[302]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[303]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[304]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[305]  A. K. Sood,et al.  Familial hyperlipidemia in stroke in the young. , 1986, Stroke.

[306]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[307]  C. Malmendier,et al.  Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. , 1985, Atherosclerosis.

[308]  C. Packard,et al.  Fenofibrate Reduces Low Density Lipoprotein Catabolism in Hypertriglyceridemic Subjects , 1985, Arteriosclerosis.

[309]  M. J. Chapman.  Animal lipoproteins: chemistry, structure, and comparative aspects. , 1980, Journal of lipid research.

[310]  M. Karvonen,et al.  A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. , 1979, British heart journal.

[311]  C. Packard,et al.  Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. , 1979, The Journal of clinical investigation.

[312]  D. Grafnetter,et al.  A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. , 1978, British heart journal.

[313]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[314]  B. Shen,et al.  Structure of human serum lipoproteins inferred from compositional analysis. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[315]  J. Stamler.  Clofibrate and niacin in coronary heart disease. , 1975, JAMA.

[316]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[317]  D. Fredrickson.  An international classification of hyperlipidemias and hyperlipoproteinemias. , 1971, Annals of internal medicine.

[318]  S. Stenson,et al.  Regression of peripheral atherosclerosis during therapy with high doses of nicotinic acid. , 1967, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[319]  L. Carlson.  Serum lipids in men with myocardial infarction. , 2009, Acta medica Scandinavica.

[320]  M. Albrink,et al.  Serum triglycerides in coronary artery disease. , 1958, Transactions of the Association of American Physicians.